Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 6/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28464496 | 1.00 | GPR119 (0.39) | GPR119RIPK1JAK2NTRK1DPP4 | |
| SCHEMBL22608877 | 1.00 | GPR119 (0.39) | GPR119RIPK1JAK2NTRK1DPP4 | |
| SCHEMBL25693076 | 1.00 | GPR119 (0.39) | GPR119RIPK1JAK2NTRK1DPP4 | |
| SCHEMBL22608917 | 1.00 | GPR119 (0.39) | GPR119RIPK1JAK2NTRK1DPP4 | |
| SCHEMBL25691756 | 1.00 | GPR119 (0.39) | GPR119RIPK1JAK2NTRK1DPP4 | |
| SCHEMBL28465515 | 0.91 | RIPK1 (0.44) | GPR119RIPK1DPP4RECQL | |
| SCHEMBL22608923 | 0.91 | RIPK1 (0.44) | GPR119RIPK1DPP4RECQL | |
| SCHEMBL25691609 | 0.91 | RIPK1 (0.44) | GPR119RIPK1DPP4RECQL | |
| SCHEMBL28461898 | 0.91 | RIPK1 (0.44) | GPR119RIPK1DPP4RECQL | |
| SCHEMBL25692074 | 0.91 | RIPK1 (0.44) | GPR119RIPK1DPP4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | GPR119 420/4885RIPK1 1/4885JAK2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.